29. Preliminary results of pembrolizumab monotherapy in recurrent or metastatic head and neck squamous cell carcinoma
Main Article Content
Abstract
This is a longitudinal and observational follow-up study to evaluate the safety and efficacy of pembrolizumab monotherapy in 56 patients with recurrent or metastatic head and neck squamous cell carcinoma at K Hospital and Hanoi Oncology Hospital from January 2019 to December 2024. The results show that complete response rate was 3.6%, partial response was 25.0%, overall response rate was 28.6%, and controlled disease in 51.8%. Patients with PD-L1-positive had higher response rate. Age, gender, smoking, prior treatment, PS, or tumor location were not related to response of pembrolizumab. Side effects related to the immune system occurred in 28.6% of cases, mostly mild; 3.6% had grade III and were manageable.
Article Details
Keywords
Squamous cell carcinoma, head and neck cancer, recurrent and metastastic, pembrolizumab
References
2. Trần Văn Thuấn, Lê Văn Quảng, Nguyễn Tiến Quang. “Ung thư đầu mặt cổ”. Hướng dẫn chẩn đoán và điều trị một số bệnh ung thư. 2019:176-187.
3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. Jan 2022; 70(1): 7-30. doi:10.3322/caac.21590.
4. International Agency for Research on Cancer WHO. GLOBOCAN 2020: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2020. Head and Neck Cancer. 8 January, 2020. 2018. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.
5. Nguyễn Bá Đức, Trần Văn Thuấn, Nguyễn Tuyết Mai. Điều trị nội khoa bệnh ung thư. vol 1. Ung thư biểu mô vảy vùng đầu cổ. Nhà xuất bản Y học; 2010:7.
6. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. Sep 11 2008; 359(11): 1116-27. doi:10.1056/NEJMoa0802656.
7. Medina PJ, Adams VR. PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune Responses. Pharmacotherapy. Mar 2016; 36(3): 317-34. doi:10.1002/phar.1714.
8. Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev. Jul 2010; 236: 219-42. doi:10.1111/j.1600-065X.2010.00923.x.
9. Network NCC. NCCN clinical practice guidelines in oncology (NCCN Guidelines™): Head and Neck cancer. Version 7.2022. 11/2022. www.nccn.org.
10. Hướng dẫn chẩn đoán và điều trị một số bệnh ung thư (Bộ Y tế - Cục quản lý khám chữa bệnh) (2020).
11. Kim H, Kwon M, Kim B, et al. Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea. BMC Cancer. Aug 5 2020; 20(1): 727. doi:10.1186/s12885-020-07214-4.
12. Sano D, Tokuhisa M, Takahashi H, et al. Real-world Therapeutic Outcomes of the Pembrolizumab Regimen as First-line Therapy for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Single-center Retrospective Cohort Study in Japan. Anticancer Res. Sep 2022; 42(9): 4477-4484. doi:10.21873/anticanres.15948.
13. Chen WC, Chu PY, Lee YT, et al. Pembrolizumab for recurrent/metastatic head and neck squamous cell carcinoma in an Asian population. Medicine (Baltimore). Dec 2017; 96(52): e9519. doi:10.1097/md.0000000000009519.
14. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. May-Jun 2024; 74(3): 229-263. doi:10.3322/caac.21834.
15. Cohen EEW, Soulières D, Le Tourneau C, et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study. Lancet. Jan 12 2019; 393(10167): 156-167. doi:10.1016/s0140-6736(18)31999-8.
16. Harrington KJ, Burtness B, Greil R, et al. Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study. J Clin Oncol. Feb 1 2023; 41(4): 790-802. doi:10.1200/jco.21.02508.